Abstract
Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1585-1589 |
| Number of pages | 5 |
| Journal | Liver International |
| Volume | 36 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 1 2016 |
Fingerprint
Keywords
- direct acting antivirals
- hepatitis C virus
- immunosuppression
- lung transplant
- sofosbuvir
ASJC Scopus subject areas
- Hepatology
Cite this
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant : case series and review of the literature. / D'Ambrosio, Roberta; Aghemo, Alessio; Rossetti, Valeria; Carrinola, Rosaria; Colombo, Massimo.
In: Liver International, Vol. 36, No. 11, 01.11.2016, p. 1585-1589.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant
T2 - case series and review of the literature
AU - D'Ambrosio, Roberta
AU - Aghemo, Alessio
AU - Rossetti, Valeria
AU - Carrinola, Rosaria
AU - Colombo, Massimo
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.
AB - Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.
KW - direct acting antivirals
KW - hepatitis C virus
KW - immunosuppression
KW - lung transplant
KW - sofosbuvir
UR - http://www.scopus.com/inward/record.url?scp=84991502904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991502904&partnerID=8YFLogxK
U2 - 10.1111/liv.13203
DO - 10.1111/liv.13203
M3 - Article
VL - 36
SP - 1585
EP - 1589
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 11
ER -